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UNCERTAINTIES PAGE
How effective is tranexamic acid for acute
gastrointestinal bleeding?
Daniela Manno clinical lecturer, Katharine Ker lecturer, Ian Roberts professor
Clinical Trials Unit, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK
This is one of a series of occasional articles that highlight areas of
practice where management lacks convincing supporting evidence. The
series adviser is David Tovey, editor in chief, the Cochrane Library. To
suggest a topic for this series, please email us at
uncertainties@bmj.com.
Acute gastrointestinal bleeding is a common emergency. It
encompasses upper gastrointestinal bleeding (such as from
peptic ulcers and oesophageal varices)1 and lower
gastrointestinal bleeding (commonly from diverticular disease,
colitis, and cancer).2 The risk is greater in older adults, and many
cases are associated with the use of non-steroidal
anti-inflammatory drugs.3
In the UK acute gastrointestinal bleeding accounts for about 75
000 hospital admissions each year and has a case fatality of
about 10%.3 4 Case fatality may be higher in patients already
hospitalised for another condition.1 More effective treatments
for acute gastrointestinal bleeding are needed.
Tranexamic acid (TXA) reduces clot breakdown by inhibiting
the action of plasmin, which is involved in fibrinolysis. A
systematic review of randomised controlled trials in surgical
patients shows that TXA, given before or during surgery,
reduces the probability of receiving a blood transfusion by about
a third (relative risk 0.62, 95% confidence interval 0.58 to 0.65).5
The effect of tranexamic acid on thromboembolic events such
as myocardial infarction, stroke, deep vein thrombosis, and
pulmonary embolism, however, was uncertain.5
The CRASH-2 trial showed that administration of TXA to
bleeding trauma patients reduced death due to bleeding (relative
risk 0.85, 0.76 to 0.96) and all cause mortality (relative risk
0.91, 0.85 to 0.97) with no apparent increase in thromboembolic
events.6 Among patients treated soon after injury, the reduction
in mortality with TXA was even greater.7
The knowledge that TXA reduces bleeding in surgery and
reduces mortality in trauma raises the possibility that it might
also be effective in gastrointestinal bleeding. Fibrinolysis may
play a role in gastrointestinal bleeding because of premature
breakdown of fibrin blood clots at the bleeding site.8 9 Many
patients with acute upper gastrointestinal bleeding have elevated
levels of fibrin degradation products (a marker of fibrinolysis),
and these patients have worse outcomes.8 9
What is the evidence of the uncertainty?
Through searches of PubMed, Embase, and the Cochrane Central
Database of Controlled Trials, we identified nine randomised
comparisons from eight clinical trials of the use of TXA in upper
gastrointestinal bleeding and none in lower gastrointestinal
bleeding (figure⇓).10-17 Seven of the identified trials were also
included in a Cochrane systematic review on the effectiveness
of TXA in upper gastrointestinal bleeding.18 The pooled result
shows a statistically significant reduction in the risk of death in
patients receiving TXA (relative risk 0.66, 0.47 to 0.93)
(figure⇓). However, the quality of the trials was poor. Only one
trial had adequate allocation concealment. In several trials,
patients were excluded after randomisation, and information on
their outcomes was not reported, raising the possibility of
selection bias. All but two trials were conducted before the
widespread use of therapeutic endoscopy and proton pump
inhibitors. Therefore, their results might not be applicable to
current patients with gastrointestinal bleeding.
We conducted a trial sequential analysis19 to assess the reliability
of the result from our systematic review andmeta-analysis. This
showed that about 5500 patients would need to have been
included in clinical trials (many more than the current total) to
have enough power to detect a plausible treatment effect. Thus,
although the meta-analysis result is statistically significant
(P<0.05), this could easily be a false positive result.
Only three trials reported data on adverse events. These studies
were already included in the previous Cochrane review.18 The
risk of thromboembolic events is about 1% overall and seemed
to be higher in TXA treated patients (relative risk 1.86, 0.66 to
5.24). However, the result is imprecise and compatible with the
play of chance.
Given these uncertainties, TXA is not routinely used or
recommended for gastrointestinal bleeding. In a UK audit in
2007, fewer than 1% of patients with upper gastrointestinal
bleeding received TXA.20 TXA is not referred to in two
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international consensus documents on the management of upper
gastrointestinal bleeding21 22 nor in the 2012 UK National
Institute for Health and Care Excellence (NICE) guidelines for
acute upper gastrointestinal bleeding.4
Is ongoing research likely to provide
relevant evidence?
Searches of the ClinicalTrials.gov trial registry suggest that
there are two ongoing double blind randomised controlled trials
of the use of intravenous TXA in gastrointestinal bleeding
(described in the table⇓). In both trials, TXA or placebo is given
in addition to the usual management of gastrointestinal bleeding.
The TAUGIB trial includes patients with acute upper
gastrointestinal bleeding before undergoing endoscopy, but it
will not be large enough to determine reliably the effect of TXA
onmortality and thromboembolic events. Assuming a mortality
of 10% in the placebo group,1 a trial of 400 patients has only
10% power to detect a 25% reduction in mortality (10% to
7.5%).
The HALT-IT trial aims to recruit 8000 patients with acute
gastrointestinal bleeding (upper or lower) and will have over
90% power to detect a 25% reduction from 10% to 7.5% in
mortality.
What should we do in the light of the
uncertainty?
TXA is not routinely recommended for upper or lower
gastrointestinal bleeding, and there are important uncertainties
about its safety and effectiveness for this indication. Uncertainty
about its effect on thromboembolic events is important, as many
patients with acute gastrointestinal bleeding are older and have
a high baseline risk of thromboembolism. In a UK survey, the
median age of patients with gastrointestinal bleeding was 68
years, with about 18% having a history of ischaemic heart
disease and 8%with a previous stroke.1Clinicians have to decide
whether to use TXA without reliable evidence of the balance
between risk and benefit. However, in the context of such
uncertainty the most appropriate management would be to
include them in a randomised controlled trial. This will ensure
that the uncertainty is resolved in a timely and scientifically
defensible way.
In the meantime, current NICE guidelines suggest the following
key points in the management of patients with upper
gastrointestinal bleeding:
• Risk assessment, with Blatchford scoring system at first
assessment and the full Rockall scoring system after
endoscopy
• Fluid resuscitation
• Localisation of the bleeding site
• Therapeutic interventions to stop bleeding, including
endoscopic treatment
• Prevention of re-bleeding.23
NICE guidelines are useful for standardising the management
of acute upper gastrointestinal bleeding. However, the evidence
base for some of the recommendations is weak.23 In addition,
no recent guidelines are available for lower gastrointestinal
bleeding. High quality research is needed to inform clinical
decisions in the management of both upper and lower
gastrointestinal bleeding.
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Table
Table 1| Trials of the use of intravenous tranexamic acid for gastrointestinal bleeding (identified from the US ClinicalTrials.gov database,
www.clinicaltrials.gov)
Primary outcomeComparisonInterventionPopulationStatusTrial (type)
Proportion of patients requiring
early endoscopic treatment
Placebo1 g IV bolus over 10 minutes
followed by 1 g slow infusion over
8 hours
414 patients with upper GI
bleeding before endoscopy
Currently recruitingTAUGIB (double blind,
randomised trial)
Mortality in hospital within 28
days of randomisation
Placebo1 g IV bolus over 10 minutes
followed by 3 g slow infusion over
24 hours
8000 patients with significant
acute GI bleeding
Currently recruitingHALT-IT (double blind,
randomised trial)
GI=gastrointestinal. IV=intravenous.
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Figure
Meta-analysis and risk of bias summary of trials assessing effect of tranexamic acid (TXA) on death in acute gastrointestinal
bleeding. All trials compared TXA with placebo unless stated otherwise
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